m-CPP hydrochloride5-HT2B/2C receptor agonist CAS# 13078-15-4 |
- Ampalex
Catalog No.:BCC1359
CAS No.:154235-83-3
- Tezampanel
Catalog No.:BCC1993
CAS No.:154652-83-2
- Noopept
Catalog No.:BCC1804
CAS No.:157115-85-0
- Perampanel
Catalog No.:BCC1847
CAS No.:380917-97-5
- Aniracetam
Catalog No.:BCC4219
CAS No.:72432-10-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 13078-15-4 | SDF | Download SDF |
PubChem ID | 25681 | Appearance | Powder |
Formula | C10H14Cl2N2 | M.Wt | 233.14 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | 1-(3-chlorophenyl)piperazine;hydrochloride | ||
SMILES | C1CN(CCN1)C2=CC(=CC=C2)Cl.Cl | ||
Standard InChIKey | MHXPYWFZULXYHT-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C10H13ClN2.ClH/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13;/h1-3,8,12H,4-7H2;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 5-HT2C/2B receptor agonist/partial agonist; displays some activity at 5-HT2A and 5-HT1 receptors. pEC50 values are 7.09, 7.2, 6.65, 5.9 and 6.5 for human recombinant 5-HT2C, 2B and 2A, bovine 5-HT1A and rat 5-HT1B receptors respectively. Suppresses locomotor activity in rats in vivo. |
m-CPP hydrochloride Dilution Calculator
m-CPP hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.2893 mL | 21.4463 mL | 42.8927 mL | 85.7854 mL | 107.2317 mL |
5 mM | 0.8579 mL | 4.2893 mL | 8.5785 mL | 17.1571 mL | 21.4463 mL |
10 mM | 0.4289 mL | 2.1446 mL | 4.2893 mL | 8.5785 mL | 10.7232 mL |
50 mM | 0.0858 mL | 0.4289 mL | 0.8579 mL | 1.7157 mL | 2.1446 mL |
100 mM | 0.0429 mL | 0.2145 mL | 0.4289 mL | 0.8579 mL | 1.0723 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Decloxizine dihydrochloride
Catalog No.:BCC5549
CAS No.:13073-96-6
- FR 122047 hydrochloride
Catalog No.:BCC7092
CAS No.:130717-51-0
- SDZ WAG 994
Catalog No.:BCC7374
CAS No.:130714-47-5
- (R)-(+)-Propranolol hydrochloride
Catalog No.:BCC6810
CAS No.:13071-11-9
- Dorzolamide HCl
Catalog No.:BCC2311
CAS No.:130693-82-2
- RP 001 hydrochloride
Catalog No.:BCC7905
CAS No.:1306761-53-4
- Ozanimod (RPC1063)
Catalog No.:BCC6533
CAS No.:1306760-87-1
- PD123319
Catalog No.:BCC5010
CAS No.:130663-39-7
- Bindarit
Catalog No.:BCC4965
CAS No.:130641-38-2
- N-(2-Hydroxyethyl)-3-(4-nitrophenyl)propylamine
Catalog No.:BCC9053
CAS No.:130634-09-2
- (R)-(+)-Corypalmine
Catalog No.:BCN2289
CAS No.:13063-54-2
- Nitidine chloride
Catalog No.:BCN4957
CAS No.:13063-04-2
- 6-O-benzoylgomisin O
Catalog No.:BCN3092
CAS No.:130783-32-3
- MDL-29951
Catalog No.:BCC4059
CAS No.:130798-51-5
- Sipatrigine
Catalog No.:BCC7847
CAS No.:130800-90-7
- Pseudolarifuroic acid
Catalog No.:BCN8048
CAS No.:130825-79-5
- 7-Oxohinokinin
Catalog No.:BCN6162
CAS No.:130837-92-2
- Scoparinol
Catalog No.:BCN6163
CAS No.:130838-00-5
- Decursinol angelate
Catalog No.:BCC9222
CAS No.:130848-06-5
- ent-kaurane-3,16,17-triol
Catalog No.:BCN6164
CAS No.:130855-22-0
- 1beta,10beta-Epoxydehydroleucodin
Catalog No.:BCN7331
CAS No.:130858-00-3
- Fmoc-Val-OSu
Catalog No.:BCC3572
CAS No.:130878-68-1
- N4-Benzoylcytidine
Catalog No.:BCC9072
CAS No.:13089-48-0
- 7-O-Acetylneocaesalpin N
Catalog No.:BCN7332
CAS No.:1309079-08-0
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.[Pubmed:10498829]
Br J Pharmacol. 1999 Sep;128(1):13-20.
1. The goal of this study was to characterize the agonist pharmacology of human 5-HT2A, 5-HT2B and 5-HT2C (VSV) receptors expressed in CHO-K1 (Chinese hamster ovary) cells. 2. We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addition of agonists. 3. Stimulation of all three receptors by 5-HT caused a robust concentration dependent increase in intracellular calcium levels. No such effect was observed from non-transfected control CHO-K1 cells. 4. The rank order of potency of agonists at the different receptor subtypes varied. Tryptamines, BW-723C86, d-norfenfluramine, Ro 60-0175 and LSD exhibited the following rank order of potency; 5-HT2B>5-HT2C>5-HT2A. Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A. The phenylisopropylamines DOI and DOB had a rank order of 5-HT2A>5-HT2B>5-HT2C. 5. Many agonists tested had partial agonist actions when compared to 5-HT, and a wide range of relative efficacies were exhibited, which was cell line dependent. For example, mCPP had a relative efficacy of 65% at 5-HT2C receptors but <25% at either 5-HT2A or 5-HT2B receptors. 6. Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex. Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same experiment using the same assay conditions and parental cell lines.
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).[Pubmed:7938165]
Pharmacol Rev. 1994 Jun;46(2):157-203.
It is evident that in the last decade or so, a vast amount of new information has become available concerning the various 5-HT receptor types and their characteristics. This derives from two main research approaches, operational pharmacology, using selective ligands (both agonists and antagonists), and, more recently, molecular biology. Although the scientific community continues to deliberate about the hierarchy of criteria for neurotransmitter receptor characterisation, there seems good agreement between the two approaches regarding 5-HT receptor classification. In addition, the information regarding transduction mechanisms and second messengers is also entirely consistent. Thus, on the basis of these essential criteria for receptor characterisation and classification, there are at least three main groups or classes of 5-HT receptor: 5-HT1, 5-HT2, and 5-HT3. Each group is not only operationally but also structurally distinct, with each receptor group having its own distinct transducing system. The more recently identified 5-HT4 receptor almost undoubtedly represents a fourth 5-HT receptor class on the basis of operational and transductional data, but this will only be definitively shown when the cDNA for the receptor has been cloned and the amino acid sequence of the protein is known. Although those 5-HT receptors that have been fully characterised and classified to date (and, hence, named with confidence) would seem to mediate the majority of the actions of 5-HT throughout the mammalian body, not all receptors for 5-HT are fully encompassed within our scheme of classification. These apparent anomalies must be recognised and need further study. They may or may not represent new groups of 5-HT receptor or subtypes of already known groups of 5-HT receptor. Even though the cDNAs for the 5-ht1E, 5-ht1F, 5-ht5, 5-ht6, and 5-ht7 receptors have been cloned and their amino acid sequence defined, more data are necessary concerning their operational and transductional characteristics before one can be confident of the suitability of their appellations. Therefore, it is important to rationalise in concert all of the available data from studies involving both operational approaches of the classical pharmacological type and those from molecular and cellular biology.(ABSTRACT TRUNCATED AT 400 WORDS)
Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity.[Pubmed:2709329]
J Pharmacol Exp Ther. 1989 Apr;249(1):155-64.
The piperazine-type 5-hydroxytryptamine (5-HT) agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP), 1-(m-chlorophenyl)-piperazine (m-CPP), 1-(p-chlorophenyl)piperazine (p-CPP) and MK-212 [6-chloro-2-(1-piperazinyl)pyrazine], produced a dose-dependent suppression of spontaneous ambulatory behavior in rats. Pretreatment with the 5-HT antagonists metergoline, methysergide or mianserin, but not selective 5-HT2 or catecholamine antagonists, blocked the reduction of activity caused by TFMPP suggesting that the stimulation of 5-HT receptors was involved in causing this behavioral effect. Other behavioral signs of 5-HT receptor stimulation, such as the 5-HT behavioral syndrome or head-shaking behavior, were not observed in rats injected with TFMPP, m-CPP or MK-212 except at toxic doses. The ability of piperazine agonists to reduce locomotor activity in rats was altered by long-term changes in 5-HT neurotransmission. The destruction of 5-HT neurons by i.v.t. injection of the neurotoxin 5,7-dihydroxytryptamine potentiated the ability of m-CPP to inhibit ambulatory behavior. On the other hand, elevating 5-HT content by administering the monoamine oxidase inhibitors phenelzine or nialamide for 7 days reduced the ability of m-CPP to suppress locomotor activity. Acute administration of the monoamine oxidase inhibitors, or chronic administration of other antidepressants such as desmethylimipramine or iprindole, failed to alter m-CPPs activity-suppressant effects. These studies suggest that chronic changes in 5-HT neurotransmission produce compensatory changes which alter the behavioral response to these piperazine agonists. Taken together with other evidence that both TFMPP and m-CPP are agonists at 5-HT1B and 5-HT1C receptors, the effects of TFMPP and m-CPP on locomotor activity may be associated with the selective activation of 5-HT1C, or possibly 5-HT1B, receptors.